MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis
Leukemia stem cells (LSCs) exhibit self-renewal, resistance to standard treatments, and involvement in leukemia relapse. Higher Myeloid Ecotropic Integration Site-1 (MEIS1) expression in leukemic blast samples has been linked to resistance to conventional treatment. We studied the MEIS1 and associated factors in relapsed LSCs and assessed the effect of recently developed MEIS inhibitors (MEISi). Meis1 gene expression was found to be higher in patients with leukemia and relapsed samples. The majority of CD123+ and CD34+ LSCs demonstrated higher MEIS1/2/3 content. Depending on the patient chemotherapy regimen, Meis1 expression increased in relapsed samples. Although there are increased Meis2, Meis3, Hoxa9, Pbx1, or CD34 expressions in the relapsed patients, they are not correlated with Meis1 content in every patient or regimen. MEISi has reduced MEIS1 transcriptional activity and LSC cell survival by apoptosis. Pharmacological targeting with MEISi in LSCs could have a potential effect in limiting leukemia relapse and chemotherapeutic resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - 65(2024), 2 vom: 01. Jan., Seite 187-198 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meriç, Neslihan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute leukemia |
|---|
| Anmerkungen: |
Date Completed 25.01.2024 Date Revised 25.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10428194.2023.2275532 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363945954 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363945954 | ||
| 003 | DE-627 | ||
| 005 | 20240125231931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2023.2275532 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1270.xml |
| 035 | |a (DE-627)NLM363945954 | ||
| 035 | |a (NLM)37902585 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meriç, Neslihan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2024 | ||
| 500 | |a Date Revised 25.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Leukemia stem cells (LSCs) exhibit self-renewal, resistance to standard treatments, and involvement in leukemia relapse. Higher Myeloid Ecotropic Integration Site-1 (MEIS1) expression in leukemic blast samples has been linked to resistance to conventional treatment. We studied the MEIS1 and associated factors in relapsed LSCs and assessed the effect of recently developed MEIS inhibitors (MEISi). Meis1 gene expression was found to be higher in patients with leukemia and relapsed samples. The majority of CD123+ and CD34+ LSCs demonstrated higher MEIS1/2/3 content. Depending on the patient chemotherapy regimen, Meis1 expression increased in relapsed samples. Although there are increased Meis2, Meis3, Hoxa9, Pbx1, or CD34 expressions in the relapsed patients, they are not correlated with Meis1 content in every patient or regimen. MEISi has reduced MEIS1 transcriptional activity and LSC cell survival by apoptosis. Pharmacological targeting with MEISi in LSCs could have a potential effect in limiting leukemia relapse and chemotherapeutic resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute leukemia | |
| 650 | 4 | |a LSCs | |
| 650 | 4 | |a MEIS inhibitor | |
| 650 | 4 | |a Meis1 | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a Homeodomain Proteins |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a Myeloid Ecotropic Viral Integration Site 1 Protein |2 NLM | |
| 650 | 7 | |a Antigens, CD34 |2 NLM | |
| 700 | 1 | |a Albayrak, Esra |e verfasserin |4 aut | |
| 700 | 1 | |a Gülbaş, Zafer |e verfasserin |4 aut | |
| 700 | 1 | |a Kocabaş, Fatih |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 65(2024), 2 vom: 01. Jan., Seite 187-198 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2024 |g number:2 |g day:01 |g month:01 |g pages:187-198 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2023.2275532 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2024 |e 2 |b 01 |c 01 |h 187-198 | ||